Director - Heart Failure Research at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Healthcare, BiotechnologyIndustries

Requirements

Ph.D. in cardiovascular biology, pharmacology, molecular biology, or a related field
5+ years of industry experience in preclinical drug discovery and development, with a proven track record of advancing therapeutic programs
Strong expertise in heart failure, including a deep understanding of its pathophysiology, preclinical models, and current therapeutic landscape
Demonstrated leadership and people-management skills, with experience mentoring and developing scientific talent
Ability to make data-driven decisions and find innovative solutions to overcome scientific and operational obstacles
Strong project management skills

Responsibilities

Provide strategic vision and direction for heart failure drug discovery and development programs, from target identification through IND-enabling studies
Lead and advise on the design, execution, and interpretation of in vivo and in vitro pharmacology studies to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of therapeutic candidates with the team
Identify robust animal models of heart failure (including HFpEF and HFrEF) and other cardiovascular diseases using internal and external resources
Serve as a subject matter expert on heart failure biology, pathology, current treatments and next generation approaches to therapeutics
Stay current with scientific literature, technology advancements, and external competitor progress to ensure the company's research remains innovative and competitive
Lead, mentor, and manage a team of junior and senior scientists, fostering a collaborative, high-performing, and innovative culture
Manage strategies, priorities, timelines and resource allocation to ensure program achievements are met efficiently
Develop comprehensive project plans and risk mitigation strategies to address scientific and operational challenges
Communicate program progress, risks, and results to senior management and cross-functional partners
Enable outsourcing activities with contract research organizations (CROs) for specialized studies, ensuring quality and prompt execution
Collaborate with cross-functional teams, including medicinal chemistry/genetic medicines/bioproducts, toxicology/ADME, bioinformatics, and regulatory affairs, to integrate data and drive program strategies
Represent the preclinical team in external meetings with scientific experts, key opinion leaders, and potential partners
Contribute pharmacology data to regulatory filings, including Investigational New Drug (IND) submissions
Support business development efforts by evaluating external opportunities for potential in-licensing

Skills

heart failure biology

pharmacology

pharmacokinetics

pharmacodynamics

in vivo studies

in vitro studies

animal models

HFpEF

HFrEF

drug discovery

target identification

IND-enabling studies

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free